Y-Intercept (HK)’s Intellia Therapeutics NTLA Stock Holding History

Y-Intercept (HK)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-35,846	Closed	-$607K	–	1941
2026 Q2	$607K	Sell	35,846 -105,235	-75%	-$1.47M	0.01%	1253
2026 Q1	$1.81M	Buy	+141,081	New	+$1.8M	0.03%	764
2025 Q4	–	Sell	-137,290	Closed	-$2.37M	–	1865
2025 Q3	$2.37M	Buy	+137,290	New	+$1.69M	0.06%	514
2025 Q1	–	Sell	-26,071	Closed	-$304K	–	1494
2024 Q4	$304K	Buy	+26,071	New	+$407K	0.02%	932

Other funds holding NTLA

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Canal Insurance Company Greenville, South Carolina $426M AUM 30.47% 1-Year Est. Return

Elmwood Wealth Management Berkeley, California $416M AUM 11.87% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return

Cyndeo Wealth Partners St. Petersburg, Florida $2.21B AUM 17.29% 1-Year Est. Return

Axxcess Wealth Management Carlsbad, California $2.44B AUM 16.42% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Y-Intercept (HK)'s NTLA Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Intellia Therapeutics (NTLA) in Q3 2026, closing a stake of 35,846 shares — an estimated $607K sold.

Y-Intercept (HK) first reported a position in NTLA in Q4 2024 and held it in 4 quarters. The position peaked at $2.37M in Q3 2025. 45 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

Y-Intercept (HK) reported no remaining Intellia Therapeutics position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 35,846 Intellia Therapeutics shares in Q3 2026, an estimated $607K.
Y-Intercept (HK) first reported a position in Intellia Therapeutics in Q4 2024 and held it in 4 quarters.
Y-Intercept (HK)'s Intellia Therapeutics position peaked at $2.37M in Q3 2025.
45 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.